|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-14.82/--
|
Enterprise Value
3.55M
|
Balance Sheet |
Book Value Per Share
14.07
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
0
|
Operating Revenue Per Share
0.38
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/01/11 17:59 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. |